Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

A chemical company registered in the U.S. signed a letter urging the Office of the U.S. Trade Representative to exclude from tariffs a product made by its Chinese government-linked parent company — without disclosing that link.

Why it matters: The tariffs remain, but the process illustrates how Chinese-owned companies registered as U.S. entities can lobby the U.S. government to change policies that negatively affect their Chinese parent companies, all without registering as foreign agents.

  • This makes it more difficult to track the potential influence of Chinese corporate- and government-linked interests on U.S. policy.

What's happening: The letter, dated Nov. 13, 2019, and addressed to U.S. Trade Representative Robert Lighthizer, says the U.S. is unable to produce enough PMDI, which is used to make insulation and other household products, to fulfill the needs of U.S. manufacturers.

  • The letter is signed by eight entities, including Wanhua Chemical U.S. Operations LLC and several U.S. roofing and construction companies, as well as an industry group, the Polyisocyanurate Insulation Manufacturers Association (PIMA).
  • In the letter, these groups state they are part of a group called the "Competitive MDI Coalition," which has no website and, unusually for a trade advocacy group, is not registered in federal lobbying databases or in the states where its members are based.
  • "We cannot emphasize enough the adverse impact the tariffs on such a critical input will have on our U.S. manufacturing of downstream products," they wrote.

The big picture: Foreign-owned companies, through their U.S.-registered affiliates, have an avenue to lobby the U.S. government not only by hiring former U.S. elected officials to press their cause, but also through industry and trade groups.

  • Wanhua Chemical is a member of several U.S. industry groups, including the American Chemistry Council and PIMA.
  • Industry groups receive funds from member companies whose contributions are disclosed only to the IRS, not publicly, a phenomenon known as "dark money."
  • The groups are allowed to spend money on donations to super PACS and lobbying.

What they're saying: "Wanhua has been very public with its problems with tariffs," Edward Brzytwa, director for international trade at the American Chemistry Council, a U.S. industry group, told Axios in an interview.

  • "For our purposes, if they’re investing in the U.S., we call them a U.S. chemical manufacturer," he said.
  • Brzytwa later added: "A company needs to manufacture chemical products in the U.S. or sell chemical products in the U.S., among other criteria, to be considered a U.S. chemical manufacturer."

The intrigue: Wanhua Chemical U.S. Operations LLC is owned by Wanhua Chemical Group, a Chinese company that is among the world's largest manufacturers (and exporters) of PMDI.

  • An investment entity owned by a Chinese municipal government is Wanhua Chemical Group's largest shareholder (21.59%), according to the company's 2019 annual report.
  • But Wanhua Chemical U.S. Operations does not disclose this relationship in the letter it signed to Lighthizer, which states it is from "consumers of PMDI."
  • In 2017, Wanhua Chemical Group announced plans to build a $1.25 billion plant to produce MDI in Louisiana, but those plans are now on hold.

Background: Wanhua Chemical U.S. Operations LLC has not registered under the Foreign Agents Registration Act (FARA), nor has Wanhua Chemical Group.

  • But lobbying firms that represent Wanhua have registered their contracts under both the FARA and Senate lobbying databases.
  • In disclosures filed with the Senate database, law firm Alston & Bird wrote, "To the extent that Wanhua Chemical (America) Co., Ltd. realizes any benefit from legislative or executive action, so, too, would its parent company, Wanhua Chemical Group Co. Ltd."
  • AUX Initiatives LLC, a DC-based government affairs consulting firm, filed a FARA registration for its contract with Wanhua Chemical US Operations LLC in August 2018 "out of an abundance of caution."

Calls to phone numbers and emails sent to addresses associated with the U.S.-based affiliates of Wanhua Chemical Group went unanswered.

Editor’s note: This story has been updated with a new quote from Brzytwa, who asked to clarify his earlier comments.

Read the letter.

Go deeper

Democrats' hypocrisy moment

Illustration: Eniola Odetunde/Axios. Photo: Ray Tamarra/Getty Images

Gov. Andrew Cuomo should be facing explicit calls to resign from President Biden on down, if you apply the standard that Democrats set for similar allegations against Republicans. And it's not a close call.

Why it matters: The #MeToo moment saw men in power run out of town for exploiting young women. Democrats led the charge. So the silence of so many of them seems more strange — and unacceptable by their own standards — by the hour.

Police officers' immunity from lawsuits is getting a fresh look

Illustration: Aïda Amer/Axios

Nearly a year after the death of George Floyd, advocates of changes in police practices are launching new moves to limit or eliminate legal liability protections for officers accused of excessive force.

Why it matters: Revising or eliminating qualified immunity — the shield police officers have now — could force officers accused of excessive force to personally face civil penalties in addition to their departments. But such a change could intensify a nationwide police officer shortage, critics say. 

The U.S. coronavirus vaccines aren't all the same

Illustration: Eniola Odetunde/Axios

The U.S. now has three COVID-19 vaccines, and public health officials are quick — and careful — to say there’s no bad option. But their effectiveness, manufacturing and distribution vary.

Why it matters: Any of the authorized vaccines are much better than no vaccine, especially for people at high risk of severe coronavirus infections. But their differences may fuel perceptions of inequity, and raise legitimate questions about the best way to use each one.